Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
CDW Corp reported net sales of $6.75 billion for the third quarter of 2026, a significant increase from $5.74 billion in the prior year period. Net income rose to $309.8 million, supported by strong operating income growth, while the company continued its capital return strategy through $652.7 million in share repurchases during the first nine months of the year.
L.B. Foster Company reported a significant increase in net income for the nine months ended September 30, 2026, reaching $11.4 million compared to $5.0 million in the prior year period. Total net sales grew by 12.7% year-over-year to $427.7 million, driven by strong performance in both goods and services segments.
Strategy Director Jarrod M. Patten Sells $129K of Stock
Jarrod M. Patten, Director, sold 950 shares of Strategy Inc at $136.04 a share, worth $129K in total on Nov 3, 2026. Shares held after the trade: 28,406 (-3.2%).
Credit Acceptance Insider Thomas N. Tryforos Buys $1.46M of Stock
Thomas N. Tryforos bought 3,000 shares of Credit Acceptance Corp at $485.20 a share, worth $1.46M in total on Nov 2, 2026. Shares held after the trade: 3,000.
Blue Owl Credit SLF LLC reported a net increase in members' equity from operations of $31.0 million for the quarter ended September 30, 2026, up from $13.3 million in the prior year period. Total assets grew significantly to $3.56 billion compared to $2.48 billion at year-end 2025, driven by an increase in investments at fair value.
Blue Owl Credit SLF LLC reported total investment income of $49.7 million for the quarter ended September 30, 2026, and a net increase in members' equity from operations of $31.0 million. Total assets grew significantly to $3.56 billion from $2.48 billion at the end of 2025, driven by an increase in investments at fair value.
Xencor reported financial results for the third quarter ended September 30, 2026, highlighting clinical progress for its lead bispecific antibody XmAb819 in renal cell carcinoma. The company ended the quarter with $412.4 million in cash and equivalents, providing a projected runway into 2028.
“Xencor’s lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a monotherapy and in combination with anti-PD(L)1 are underway, with evaluation of XmAb819 in additional ENPP3-positive tumor types also ongoing.”
Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor
Cirrus Logic reported Q2 FY2027 revenue of $559.5 million and GAAP EPS of $2.23, driven by strong demand for smartphone components. The company also announced that its Board of Directors authorized an additional $500 million for its stock repurchase program.
“Cirrus Logic delivered solid results in the September quarter primarily driven by strong demand and increased content shipping into smartphones. During the quarter we were pleased to see our custom components featured in newly launched smartphones, in addition to broader adoption of our third-generation camera controller in these devices.”
John Forsyth, Cirrus Logic president and chief executive officer
“We also made progress on new product development as we began sampling our analog front-end components for smart metering and taped out both our fourth-generation camera controller for smartphones and second-generation smart codec for AI-enabled PCs. With an extensive roadmap and strong pipeline of opportunities, we remain confident in our ability to grow long-term shareholder value.”
John Forsyth, Cirrus Logic president and chief executive officer
Apollo IG Core Replacement, L.P. issued unregistered limited partnership interests for aggregate cash consideration of approximately $478.8 million on November 1, 2026. The sale was conducted as part of the company's continuous private offering. Additionally, the company reported a Net Asset Value (NAV) of $1,295.5 million as of September 30, 2026.
Edgewise Therapeutics reported 109,482,763 shares of common stock outstanding as of October 31, 2026. The company is focusing its resources on the development of EDG-7500 and EDG-15400 following the Sevasemten Sale, which has impacted its operating expenses and cash position.
Purple Innovation reported a net loss of $35.2 million for the nine months ended September 30, 2026, an improvement from a $48.3 million loss in the prior year period. Revenues decreased 11.4% year-over-year to $290.5 million, while the company significantly reduced its operating loss through lower marketing and sales expenses and reduced restructuring charges.
Edgewise Therapeutics reported Q3 2026 financial results, highlighting a $1.348 billion gain from the sale of sevasemten to Servier. The company ended the quarter with $1.74B in cash and is on track to initiate a Phase 3 trial for EDG-7500 in HCM by year-end 2026.
“Our third quarter reflects continued execution across both cardiovascular programs. In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.”
Kevin Koch, Ph.D., President and Chief Executive Officer
Niagen Bioscience reported a net loss of $1.2 million for the third quarter of 2026, a significant decline from a $4.6 million profit in the prior year, driven by a 20% decrease in net sales. However, for the nine-month period, the company remained profitable with a net income of $6.1 million, bolstered by a $4.8 million gain from the sale of an operating segment.
ARKO Petroleum Corp. reported third quarter 2026 net income of $13.3 million and Adjusted EBITDA of $41.0 million, representing year-over-year growth. The company raised its full-year 2026 Adjusted EBITDA guidance and declared a quarterly dividend of $0.50 per share.
Term
Q3 2026
“APC’s third-quarter results reinforce the strategy we outlined at the IPO. Adjusted EBITDA and Discretionary Cash Flow grew year over year, which we believe demonstrated the durability of our platform, the stability of its cash generation and our team’s ability to execute effectively through a volatile market environment. Based on year-to-date performance, our outlook for the balance of the year and the expected closing of USPP, we are raising our full-year 2026 Adjusted EBITDA guidance.”
Arie Kotler, Chairman, President and Chief Executive Officer of APC
MercadoLibre reported third-quarter 2026 net revenues of $10.75 billion, a 45% increase year-over-year, driven by strong performance in Brazil and deepening ecosystem engagement. Net income for the period was $448 million, while income from operations decreased 6% to $676 million due to investments in free shipping, fulfillment capacity, and marketing.
AGL Private Credit Income Fund reported total assets of $1.54 billion as of September 30, 2026, with a portfolio primarily consisting of non-controlled, non-affiliated investments valued at $1.46 billion. The fund maintained 27,060,888 common shares outstanding and reported total debt of $861.6 million, net of deferred financing costs.
Moleculin Biotech announced that interim data from its pivotal Phase 2/3 trial (MB-108) of Annamycin for relapsed or refractory AML will be presented at the 2026 ASH Annual Meeting. The data showed complete remission rates of 43% and 36% in the treatment arms compared to 12% for placebo, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended the study continue without amendment.
Microsoft $25B Debt Financing with J.P. Morgan Securities LLC
Microsoft Corporation entered into an underwriting agreement for the issuance and sale of $25 billion in aggregate principal amount of senior notes across ten different tranches. The offering includes both floating rate and fixed rate notes with maturities ranging from 2028 to 2066, with J.P. Morgan, UBS, and Wells Fargo acting as representatives for the underwriters.
Allegiant Travel Company reported third quarter 2026 financial results, including a GAAP net loss of $15.2 million and an adjusted diluted loss per share of $0.03. The results reflect the first full quarter of operations following the acquisition of Sun Country, with total operating revenue increasing 71.1% year-over-year to $961.6 million.
Term
Q3 2026
“Allegiant delivered another quarter of operating profitability, expanding our adjusted operating margin by 340 basis points year over year on a pro forma basis in our seasonally slowest quarter, despite a more than 55 percent surge in fuel costs per gallon.”
Greg Anderson, chief executive officer of Allegiant Travel Company
“With strong booking momentum, we remain confident in our 2026 full-year adjusted earnings per share guidance of greater than $6.00, despite elevated fuel costs.”
Greg Anderson, chief executive officer of Allegiant Travel Company
Niagen Bioscience reported Q3 2026 net sales of $27.2 million and a net loss of $1.2 million, while generating $2.6 million in operating cash flow. The company launched several new products including Niagen NanoCloud topical and an at-home injection kit, while expanding retail distribution through Walmart.com, GNC, and Sam's Club.
Term
Q3 2026
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform. We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”
ADC Therapeutics announced updated clinical data for ZYNLONTA from several trials, including the LOTIS-7 Phase 1b study which showed an 88.7% overall response rate and 75.3% complete response rate in relapsed or refractory large B-cell lymphoma. The data, which will be presented at the ASH Annual Meeting, also highlighted a 93% ORR in marginal zone lymphoma and results from the Phase 3 LOTIS-5 study. These findings support the company's plans to advance ZYNLONTA into Phase 3 studies for expanded indications.
Terreno Realty Corp reported net income of $195.1 million for the nine months ended September 30, 2026, a decrease from $244.8 million in the prior year period primarily due to lower gains on real estate sales. Total revenues increased to $381.4 million from $338.9 million, while the company continued to expand its portfolio with $326.9 million in property acquisitions during the period.
ARKO Corp. subsidiary ARKO Petroleum Corp. reported third quarter 2026 net income of $13.3 million and Adjusted EBITDA of $41.0 million. Based on year-to-date performance and the pending acquisition of U.S. Petroleum Partners, LLC, the company raised its full-year 2026 Adjusted EBITDA guidance and declared a $0.50 per share quarterly dividend.
“APC’s third-quarter results reinforce the strategy we outlined at the IPO. Adjusted EBITDA and Discretionary Cash Flow grew year over year, which we believe demonstrated the durability of our platform, the stability of its cash generation and our team’s ability to execute effectively through a volatile market environment. Based on year-to-date performance, our outlook for the balance of the year and the expected closing of USPP, we are raising our full-year 2026 Adjusted EBITDA guidance.”
Arie Kotler, Chairman, President and Chief Executive Officer of APC
Liquidity Services EVP, Chief Commercial Officer John Daunt Sells $32K of Stock
John Daunt, EVP, Chief Commercial Officer, sold 715 shares of Liquidity Services Inc at $44.71 a share, worth $32K in total on Nov 2, 2026. Shares held after the trade: 38,086 (-1.0%).
Fate Therapeutics CFO Kamal Adawi Sells $13.5K of Stock
Kamal Adawi, CFO, sold 6,582 shares of Fate Therapeutics Inc at $2.05 a share, worth $13.5K in total on Nov 3, 2026. Shares held after the trade: 93,418 (-6.6%).
Damora Therapeutics reported a significant increase in operating expenses for the nine months ended September 30, 2026, totaling $102.7 million compared to $9.2 million in the prior year, primarily driven by R&D for candidates DMR-001, DMR-002, and DMR-003. The company ended the period with $528.5 million in cash and marketable securities following a substantial increase in ordinary shares outstanding to 61.9 million.
Magnolia Oil & Gas reported Q3 2026 net income of $80.5 million and adjusted net income of $166.3 million, driven by a 17% year-over-year increase in production to 117.3 Mboe/d. The results include the partial-period impact of the WildFire Energy acquisition, which closed during the quarter. The company also increased its share repurchase authorization by 15 million shares and generated $223.7 million in adjusted free cash flow.
Term
Q3 2026
“Magnolia continues to execute at a high level as we successfully integrate the WildFire assets. Although our third quarter results include only a partial period of ownership following the September closing, the benefits of the combined asset base are already clearly evident. Our business generated $224 million of adjusted free cash flow during the quarter, with a reinvestment rate of just 38 percent of adjusted EBITDAX.”
Neogen Corporation provided a status update on the pending sale of its global Genomics business to Zoetis Inc. To facilitate regulatory clearance from the ACCC and NZCC, Zoetis has offered to divest certain assets in Australia, with the transaction now expected to close in early 2027.
Bayview Acquisition Corp received notice that the Nasdaq board of directors declined to review a prior decision to delist the company's securities. Nasdaq will proceed with filing a Form 25-NSE to formally remove the company's units, ordinary shares, and rights from listing. The company is currently seeking to have its ordinary shares quoted on the OTC Pink Market.
Expedia Group reported Q3 2026 financial results, exceeding guidance with 12% revenue growth and 11% gross bookings growth year-over-year. The company also increased its full-year 2026 guidance and declared a quarterly cash dividend of $0.48 per share.
Term
Q3 2026
“We exceeded the high end of our guidance in the quarter, reflecting resilient travel demand and strong execution. We continue to deliver traveler value through more personalized and rewarding product experiences, improve supply across our marketplace, and advance our strategy to build the one-stop travel platform for B2B partners.”